Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPC

Exclusion Criteria

• •1. Patients with prostatic histopathology exhibiting neuroendocrine, small cell, or sarcomatoid features.
• •2. The researchers assessed the primary lesion as unresectable.
• •3. Patients who had previously received androgen deprivation therapy (including medical or surgical castration) for more than 3 months, or had undergone focal therapy for prostate cancer, or had received radiotherapy or chemotherapy for prostate cancer.
• •4. Patients with severe or uncontrolled underlying diseases who could not tolerate surgery or radiotherapy.
• •5. Patients with New York Heart Association (NYHA) Class III/IV congestive heart failure, unstable angina, or a history of myocardial infarction within the past 6 months.
• •6. Uncontrolled severe hypertension, persistently uncontrolled diabetes, oxygen-dependent pulmonary disease, chronic liver disease, or HIV infection.
• •7. Within the past 5 years, having had other malignant tumors except for prostate cancer, with the exception of cured basal or squamous cell skin cancer.
• •8. Suffering from mental illness, mental disability, or being incapable of providing informed consent.